Kontafarma China Holdings Limited provided consolidated earnings guidance for the year ended 31 December 2023. For the period, the group is expected to record a consolidated net loss in the region of approximately HKD 49.0 million to HKD 73.6 million for the Fiscal Year 2023, compared to the consolidated net loss of approximately HKD 52.8 million for the year ended 31 December 2022 (after consolidating the Group's loss after tax from continuing operations of approximately HKD 109.7 million and profit after tax from discontinued operation of approximately HKD 56.9 million for the Fiscal Year 2022). The expected consolidated net loss for the Fiscal Year 2023 was attributable to the continuing operations of the Group, which is primarily due to the following factors: (i) the decrease in revenue and gross profit in the pharmaceutical business segment of the Group as a result of (a) the adverse impact caused by the medical insurance policy adjustment in Mainland China; (b) shrinking customer demand under the impact of weak macro-economy; and (c) the disposal of subsidiaries in this segment; and (ii) the increase in expected credit losses on receivables of the Group for the Fiscal Year 2023 as compared to the Fiscal Year 2022.